Stocktoria
QuidelOrtho Corp QDEL
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 1991-02-01
QuidelOrtho Corp financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $2.7B | $2.8B | $3.0B | $3.3B | $1.7B |
| R&D expense | $186.2M | $218.7M | $245.0M | $187.9M | $95.7M |
| SG&A expense | $746.3M | $766.8M | $763.2M | $621.0M | $239.6M |
| Operating income | -$919.2M | -$2.0B | $139.1M | $843.7M | $906.0M |
| Income tax | $24.1M | -$79.5M | -$19.0M | $187.2M | $196.1M |
| Net income | -$1.1B | -$2.1B | -$10.1M | $548.7M | $704.2M |
| EPS (diluted) | $-16.69 | $-30.54 | $-0.15 | $9.56 | $16.43 |
| Operating cash flow | $105.2M | $83.0M | $280.2M | $885.3M | $805.9M |
| Free cash flow | -$83.0M | -$112.1M | $70.9M | $744.4M | $513.1M |
| Cash & equivalents | $169.8M | $98.3M | $118.9M | $292.9M | $802.8M |
| Inventory | $577.6M | $533.7M | $577.8M | $524.1M | $198.8M |
| Total assets | $5.8B | $6.4B | $8.6B | $8.9B | $2.4B |
| Total liabilities | $3.8B | $3.4B | $3.6B | $3.9B | $501.0M |
| Shareholders' equity | $1.9B | $3.0B | $5.0B | $4.9B | $1.9B |
Source: SEC EDGAR filings · CIK 0001906324 · as of 2025-12-28. Facts from filings plus Stocktoria's own computed scores — not investment advice.